Source: European Medicines Agency (EU) Revision Year: 2018 Publisher: Roche Registration GmbH, Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Germany
INVIRASE 500 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Light orange to greyish or brownish orange film-coated tablet of oval cylindrical biconvex shape with the marking “SQV 500” on the one side and “ROCHE” on the other side. |
One film-coated tablet contains 500 mg of saquinavir as saquinavir mesilate.
Excipient with known effect: Lactose monohydrate: 38.5 mg.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Saquinavir |
Saquinavir selectively inhibits the HIV protease, thereby preventing the creation of mature infectious virus particles. The HIV protease is an essential viral enzyme required for the specific cleavage of viral gag and gag-pol polyproteins. |
| List of Excipients |
|---|
|
Tablet core: Microcrystalline cellulose Tablet coat: Hypromellose |
Plastic bottles (HDPE) containing 120 tablets.
Roche Registration GmbH, Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Germany
EU/1/96/026/002
Date of first authorisation: 04 October 1996
Date of latest renewal: 04 October 2006
| Drug | Countries | |
|---|---|---|
| INVIRASE | Austria, Australia, Cyprus, Estonia, Hong Kong, Ireland, Lithuania, Netherlands, Poland, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
